This finding suggests a need for further investigation into the heterogeneity of HR-positive/ERBB2-negative tumors using gene expression analysis and into the tumor immune microenvironment to provide insight into racial disparities in breast cancer clinical outcomes. The gene discussed is ERBB2; the disease is breast cancer.